Biohaven Ltd. (BHVN)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Biohaven Ltd. (BHVN)
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
Key Insights
Critical company metrics and information
Share Price
$44.80Market Cap
$4.53 BillionTotal Outstanding Shares
101.12 Million SharesTotal Employees
239Dividend
No dividendIPO Date
September 23, 2022SIC Description
Pharmaceutical PreparationsHomepage
https://www.biohavenpharma.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow, Continuing | $-154.30 Million |
Net Cash Flow From Financing Activities, Continuing | $80.38 Million |
Net Cash Flow From Investing Activities, Continuing | $-93.40 Million |
Exchange Gains/Losses | $0.00 |
Net Cash Flow From Financing Activities | $80.38 Million |
Net Cash Flow From Operating Activities | $-141.28 Million |
Net Cash Flow | $-154.30 Million |
Net Cash Flow From Operating Activities, Continuing | $-141.28 Million |
Net Cash Flow From Investing Activities | $-93.40 Million |
Income Statement
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Basic Average Shares | $94.37 Million |
Income/Loss From Continuing Operations After Tax | $-160.30 Million |
Operating Income/Loss | $-178.17 Million |
Income Tax Expense/Benefit | $59000.00 |
Net Income/Loss | $-160.30 Million |
Diluted Earnings Per Share | $1.70 |
Diluted Average Shares | $94.37 Million |
Revenues | $0.00 |
Income/Loss From Continuing Operations Before Tax | $-160.36 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Net Income/Loss Available To Common Stockholders, Basic | $-160.30 Million |
Basic Earnings Per Share | $1.70 |
Net Income/Loss Attributable To Parent | $-160.30 Million |
Nonoperating Income/Loss | $17.80 Million |
Costs And Expenses | $178.17 Million |
Research and Development | $157.61 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Balance Sheet
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Noncurrent Assets | $70.02 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Liabilities | $194.52 Million |
Assets | $510.52 Million |
Other Current Assets | $385.33 Million |
Intangible Assets | $18.40 Million |
Current Liabilities | $152.29 Million |
Other Current Liabilities | $116.67 Million |
Accounts Payable | $19.74 Million |
Wages | $15.88 Million |
Other Non-current Assets | $33.35 Million |
Current Assets | $440.50 Million |
Prepaid Expenses | $55.17 Million |
Equity | $316.01 Million |
Equity Attributable To Parent | $316.01 Million |
Noncurrent Liabilities | $42.22 Million |
Liabilities And Equity | $510.52 Million |
Fixed Assets | $18.28 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.